本文選題：帕金森病 + 磷酸二酯酶�。� 參考：《中國藥理學(xué)與毒理學(xué)雜志》2017年05期

【摘要】：帕金森疾病是一種常見的與年齡相關(guān)的神經(jīng)退行性疾病,隨年齡增長,發(fā)病幾率增大,多發(fā)病于中老年人群中,其病理特征主要是紋狀體區(qū)的多巴胺含量減少,發(fā)病機(jī)制復(fù)雜,至今尚不明確。目前,帕金森的治療以維持多巴胺和乙酰膽堿平衡為主要治療手段。治療帕金森病的主要有多巴胺能藥和抗膽堿藥。但是副作用較大,且只能緩解癥狀而不能阻止神經(jīng)退化。近年來的研究發(fā)現(xiàn)磷酸二酯酶家族生理作用廣泛,得到越來越多學(xué)者的關(guān)注。其中磷酸二酯酶1中的磷酸二酯酶1B參與神經(jīng)系統(tǒng)的多項(xiàng)生理活動(dòng),有多種中藥提取物對(duì)其具有抑制作用,磷酸二酯酶1B抑制劑對(duì)認(rèn)知功能障礙有一定的改善作用,并在臨床用于帕金森病的治療。中藥治療帕金森可彌補(bǔ)西藥治療的缺陷,具有毒副作用小,療效持久的特點(diǎn),是帕金森藥物治療的研究熱點(diǎn)。中藥治療具有明顯的優(yōu)勢(shì)和一定的發(fā)展前景,本文根據(jù)近年文獻(xiàn)綜述生物堿類中藥對(duì)帕金森疾病治療的可行性。
[Abstract]:Parkinson's disease is a common age-related neurodegenerative disease. The incidence of Parkinson's disease increases with age. The pathological features of Parkinson's disease are the decrease of dopamine in the striatum and the complicated pathogenesis. It is not clear yet. At present, Parkinson's treatment is to maintain dopamine and acetylcholine balance as the main treatment. The main treatments for Parkinson's disease are dopaminergic and anticholinergic drugs. But the side effect is big, and can alleviate symptom only but cannot prevent nerve degeneration. In recent years, researchers have found that phosphodiesterase family has a wide range of physiological functions, and has attracted more and more attention. Phosphodiesterase 1B in phosphodiesterase 1 is involved in many physiological activities of the nervous system, and some traditional Chinese medicine extracts have inhibitory effects on it, and phosphodiesterase 1B inhibitor can improve cognitive dysfunction to some extent. And used in clinical treatment of Parkinson's disease. Traditional Chinese medicine treatment of Parkinson's disease can make up for the defect of western medicine treatment, it has the characteristics of little side effect and lasting curative effect, so it is the research hotspot of Parkinson's drug therapy. Chinese medicine therapy has obvious advantages and certain development prospects. This paper reviews the feasibility of alkaloid Chinese medicine in the treatment of Parkinson's disease according to the literature in recent years.
【作者單位】： 河北北方學(xué)院;
【分類號(hào)】：R742.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 朱雪紅;耿昌明;;帕金森疾病相關(guān)蛋白DJ-1與微管相關(guān)蛋白MAP8的關(guān)系初步研究[J];現(xiàn)代預(yù)防醫(yī)學(xué);2012年01期

2 魏大木;熊莉麗;郝靜;茆燦泉;;σ-共核蛋白在帕金森疾病中的功能[J];安徽農(nóng)業(yè)科學(xué);2013年31期

3 ;[J];;年期

相關(guān)碩士學(xué)位論文 前1條

1 彭娟;調(diào)控帕金森疾病相關(guān)基因的miRNA研究[D];南昌大學(xué);2011年

，

本文編號(hào)：1999234